ClinicalTrials.gg
CompletedNCT07940517Updated Nov 17, 2026

PECS II Block Versus Intravenous Lidocaine for Analgesia in Breast Surgery

An interventional study of Ultrasound-Guided PECS II Block and Lidocaine (without epinephrine) in Breast Surgery and Lidocaine Infusion, sponsored by Istanbul Medeniyet University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Istanbul Medeniyet University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Nov 2023, registered Nov 2026).
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,099 studies in Pain, Postoperative with a site in Turkey — 264 open to participants now, 297 under way, none of them phase 3. Pain, Postoperative · Turkey.

Enrollment
463rd of 884
66 · median 70
Started
2023
with 132 others
No phase
815 of 1,099
217 open now
Registered
1,097th of 1,099
by date

Among the 1,099 studies in Pain, Postoperative with a site in Turkey, this one is the 463rd largest by enrollment of the 884 interventional ones that give a count, is one of 133 that started in 2023, is one of 815 with no phase, and was the 1,097th registered.

Pain, Postoperative

5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

264 of the 1,099 studies in Pain, Postoperative with a site in Turkey are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,099 studies in Pain, Postoperative with a site in Turkey, or all of them as a file.
02

Study summary

The goal of this clinical trial was to compare two methods of pain control in adults having breast-conserving surgery. The study compared a chest wall nerve block called a PECS II block with lidocaine given through a vein during surgery.

The main question it aimed to answer was:

  • Does a PECS II block lower the amount of opioid pain medicine needed during the first 12 hours after surgery compared with intravenous lidocaine? The study also looked at pain scores after surgery and the amount of remifentanil needed during surgery.

Researchers compared participants who received a PECS II block before surgery with participants who received intravenous lidocaine during surgery.

Participants:

  • Received either a PECS II block before surgery or intravenous lidocaine during surgery
  • Had their pain scores and pain medicine use recorded for up to 12 hours after surgery
03

Conditions studied

  • Breast Surgery
  • Lidocaine Infusion

Keywords

  • PECS block
  • Intravenous lidocaine
  • Postoperative pain
  • breast cancer
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Age 18 to 75 years

  • (ASA) physical status I-III
  • Scheduled for elective unilateral breast-conserving surgery
  • Written

Exclusion Criteria:

  • Refusal to participate
  • ASA physical status IV or higher
  • Cardiac arrhythmia
  • Psychiatric disorder
  • Neurodegenerative disease
  • Bleeding disorder or coagulopathy
  • Allergy to local anesthetics
  • Infection at the injection site
  • below 18 or above 35 kg/m2
  • History of opioid use
  • History of chronic pain -
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    PECS II Block

    Participants received an ultrasound-guided PECS II block at least 30 minutes before surgery. A total of 20 mL of 0.25% bupivacaine was injected between the pectoralis minor and serratus anterior muscles, followed by 10 mL of 0.25% bupivacaine between the pectoralis major and pectoralis minor muscles.

    Procedure: Ultrasound-Guided PECS II Block

  • Experimental
    Intravenous Lidocaine Infusion

    Participants received intravenous lidocaine beginning immediately before the surgical incision. A bolus dose of 1.5 mg/kg lidocaine was given intravenously, followed by a continuous intraoperative infusion of 2 mg/kg/hour until the end of surgery.

    Drug: Lidocaine (without epinephrine)

Interventions

  • ProcedureUltrasound-Guided PECS II Block

    An ultrasound-guided PECS II block was performed at least 30 minutes before surgery. A total of 20 mL of 0.25% bupivacaine was injected between the pectoralis minor and serratus anterior muscles, followed by 10 mL of 0.25% bupivacaine between the pectoralis major and pectoralis minor muscles.

    Also known as: Interpectoral and Pectoserratus Plane Block

  • DrugLidocaine (without epinephrine)

    lidocaine was administered intravenously immediately before the surgical incision as a 1.5 mg/kg bolus, followed by a continuous intraoperative infusion of 2 mg/kg/hour until the end of surgery.

06

What researchers measure

Primary outcomes

  1. Postoperative tramadol consumption

    Cumulative tramadol consumption (mg) via patient-controlled analgesia (1 mg/mL, 10 mg bolus, 6-minute lockout, no background infusion). Follow-up was planned for 24 hours after surgery; because patients were discharged at postoperative hour 12, consumption was recorded at 1, 4, 8 and 12 hours.

    Time frame: Up to 12 hours after surgery

Secondary outcomes

  1. Postoperative Pain Score

    ain intensity assessed by a blinded anesthesiologist using the 0-10 Numeric Rating Scale (0 = no pain, 10 = worst imaginable pain). An additional assessment at 24 hours was planned but could not be performed because patients were discharged at postoperative hour 12.

    Time frame: 15 minutes and 1, 4, 8 and 12 hours after surgery

07

Study locations

1 site
  • Istanbul Medeniyet University Prof. Dr. Süleyman Yalçın City Hospital
    Istanbul, Turkey (Türkiye)
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Jan 2024, 2 months.

Of 2,097 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's 2 months is below that.

Counting every sponsor, half of 2,110 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2026
First posted
Nov 17, 2026
StartActual
Nov 1, 2023
Primary completionActual
Jan 26, 2024
CompletionActual
Jan 27, 2024
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07940517
Responsible party
Deniz Bahar Akkuş (Specialist in Anesthesiology and Reanimation, Istanbul Medeniyet University) — Principal investigator
First posted
Nov 17, 2026
Start date
Nov 1, 2023
Primary completion
Jan 26, 2024
Completion
Jan 27, 2024
Last update
Nov 17, 2026

Study contacts

Zeynep Nur ORHON, Assoc. Prof., MD
principal investigator · Istanbul Medeniyet University
Deniz Bahar Akkuş, MD
principal investigator · Istanbul Medeniyet University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion